164 related articles for article (PubMed ID: 31621593)
1. Research digest: new horizons in heart failure therapy.
Sattar N; Preiss D
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):832. PubMed ID: 31621593
[No Abstract] [Full Text] [Related]
2. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
[No Abstract] [Full Text] [Related]
3. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
4. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
5. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
Sano M; Goto S
Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
[No Abstract] [Full Text] [Related]
6. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest.
Patoulias D; Papadopoulos C; Katsimardou A; Doumas M
Am J Cardiol; 2021 Jan; 139():134-136. PubMed ID: 33075281
[No Abstract] [Full Text] [Related]
7. Heart Failure and Diabetes: Perspective of a Dangerous Association.
Favaloro LE; Ratto RD; Musso C
Curr Hypertens Rev; 2021; 17(2):85-93. PubMed ID: 33823781
[TBL] [Abstract][Full Text] [Related]
8. DAPA-HF study: Are the benefits uniform across non-diabetic subgroups.
Pareek A; Rajput R; Kumar Chopra H; Dharmadhikari S
Indian Heart J; 2020; 72(5):469-470. PubMed ID: 33189217
[No Abstract] [Full Text] [Related]
9. Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors.
Vaduganathan M; Januzzi JL
Am J Cardiol; 2019 Dec; 124 Suppl 1():S20-S27. PubMed ID: 31741436
[TBL] [Abstract][Full Text] [Related]
10. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
[TBL] [Abstract][Full Text] [Related]
11. Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment.
Packer M
Am J Med; 2020 Jul; 133(7):781-782. PubMed ID: 32061625
[No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors may offer benefit beyond diabetes.
Kang A; Jardine MJ
Nat Rev Nephrol; 2021 Feb; 17(2):83-84. PubMed ID: 33361782
[No Abstract] [Full Text] [Related]
13. Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors.
Butler J
Am J Cardiol; 2019 Dec; 124 Suppl 1():S1-S2. PubMed ID: 31741434
[No Abstract] [Full Text] [Related]
14. Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction.
Wakisaka M; Kamouchi M; Kitazono T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726765
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction.
Patoulias D; Papadopoulos C; Doumas M
Eur J Intern Med; 2021 May; 87():100-101. PubMed ID: 33632595
[No Abstract] [Full Text] [Related]
16. Sodium-glucose co-transporter 2 inhibitors: 'a tale of two sisters', diabetes and heart failure.
Farmakis D; Butler J; Filippatos G
Eur J Heart Fail; 2020 Jul; 22(7):1259-1262. PubMed ID: 32533724
[No Abstract] [Full Text] [Related]
17. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
18. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
[TBL] [Abstract][Full Text] [Related]
19. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
20. EMPA-REG - the "diuretic hypothesis".
McMurray J
J Diabetes Complications; 2016; 30(1):3-4. PubMed ID: 26597600
[No Abstract] [Full Text] [Related]
[Next] [New Search]
